Soft Tissue Sarcoma Articles | Page 2

Doxorubicin/Ifosfamide Combo for Sarcoma Most Effective in Select Population
Chemotherapy with doxorubicin and ifosfamide improved progression-free survival and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients.
Apatinib Shows Potential in Advanced Sarcoma
Chinese researchers have concluded that the oral VEGFR2 inhibitor apatinib demonstrated efficacy with tolerable toxicity in a small study of patients with stage IV sarcoma, according to results published in Oncotarget.
Comprehensive Genomic Profiling Could Improve Diagnoses, Treatment in Sarcoma
Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling into sarcoma management could result in more precise diagnosis and subclassification of the disease.
Exceptional Responder to Pembrolizumab Guides Immunotherapy Progress in Leiomyosarcoma
Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.
Survivors of Ewing Sarcoma Appear to Have Only Minor Long-Term Limitations
Researchers concluded that survivors of Ewing sarcoma are largely free of physical limitations and there is little apparent difference between survivors and healthy people in terms of mental health.
A Call for Molecular Profiling in Uterine Carcinosarcoma
Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.
Chemotherapy Approach Avoids Amputation in Sarcoma Patients
John E. Mullinax, MD, discusses isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma.
Novel Compound GPX-150 Shows Promise in Soft Tissue Sarcoma
Brian Van Tine, MD, PhD, discusses the potential of the investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and nonresectable soft tissue sarcoma.
EBRT Lowers Local Recurrence Risk in Soft Tissue Sarcoma
Markus Albertsmeier, MD, discusses the results of the meta-analysis and the implications going forward for the treatment of patients with soft tissue sarcoma.
PD-1 Blockade Potential Comes to Light in Sarcoma Subtypes
An immunohistochemistry analysis of a large patient population demonstrated that several subtypes of difficult-to-treat sarcomas may respond to treatment with PD-1 pathway inhibiting immunotherapies, according to findings presented at the 2017 European Cancer Congress in Amsterdam.
Publication Bottom Border
Border Publication